in-license

1 stories · following the connections

Business

Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121

By Nasdaq OMXJul 7, 2017, 12:30 PM UTC